Skip to main content
EVGN
NASDAQ Industrial Applications And Services

Evogene's Herbicide Project with Bayer Terminated Due to Failed Target Protein

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.7
Mkt Cap
$8.471M
52W Low
$0.7
52W High
$2.42
52W Position info
0.0% above low
Off High info
71% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

EVGN is trading near its 52-week low of $0.7 (0.0% above the low).

Summary

Evogene's subsidiary Ag Plenus and Bayer have terminated their herbicide development project, citing the target protein's failure to meet product criteria, a significant blow to Evogene's R&D pipeline amidst its ongoing financial and compliance challenges.


Key Events · Product Development and Regulatory · EVGN

  • Herbicide Project Termination

    Evogene's subsidiary Ag Plenus Ltd. and Bayer AG have mutually decided to discontinue their herbicide development project, effective May 18, 2026.

  • Failure to Meet Criteria

    The project was terminated because the target protein, APTH1, did not meet the required product criteria, indicating a setback in the R&D pipeline.

  • Asset Reversion

    All licensed assets, including the APTH1 protein target and associated active molecules, will revert to Ag Plenus under the terms of the termination.

  • Context of Company Distress

    This development comes as Evogene faces substantial doubt about its going concern status and has received a formal Nasdaq delisting notice for non-compliance with the minimum bid price rule.


Analysis · EVGN · Industrial Applications And Services

The discontinuation of a key herbicide development project with Bayer is a significant setback for Evogene, especially given the company's current precarious financial position and recent Nasdaq delisting notice. For a company heavily reliant on its R&D pipeline, the failure of a collaboration with a major partner like Bayer due to unmet product criteria raises serious questions about its future product viability and ability to generate revenue. While the assets revert, the inability to progress a promising project adds to the negative sentiment surrounding the company's operational and financial health.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVGN was trading at $0.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $0.70 to $2.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVGN - Latest Insights

EVGN
Nov 19, 2026, 7:12 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.3233
Real-time Price: $0.330 info
Change: +$0.0067 (+2%) info
Market Cap: $5.651M info
EVGN
Nov 16, 2026, 7:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3646
Real-time Price: $0.330 info
Change: -$0.0346 (-9%) info
Market Cap: $5.651M info
EVGN
Oct 06, 2026, 4:00 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $0.4101
Real-time Price: $0.330 info
Change: -$0.0801 (-20%) info
Market Cap: $5.651M info
EVGN
Sep 30, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4168
Real-time Price: $0.330 info
Change: -$0.0868 (-21%) info
Market Cap: $5.651M info
EVGN
Sep 28, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3907
Real-time Price: $0.330 info
Change: -$0.0607 (-16%) info
Market Cap: $5.651M info